Figure 3. . Probability of achieving ≥90% reduction in the monthly HAE attack rate for (A) lanadelumab 300 mg Q2W and (B) lanadelumab 300 mg Q4W versus other treatment options.

ARR: Absolute risk reduction; BIW, Twice weekly; C1-INH: C1 inhibitor; HAE: Hereditary angioedema; Q2W: Every 2 weeks; Q4W: Every 4 weeks; q.d.: Once daily.